Nextstellis is an oral contraceptive drug owned by Mayne Pharma. It contains the active ingredients Drospirenone and Estetrol. This drug, which comes in tablet form, was first authorized for market use on 15 April 2021. Nextstellis holds a total of 2 patents.
The generics of Nextstellis can only be made available after the patent expiry. The last patent of Nextstellis is set to expire on 17 June, 2036. Any drug patent challenges against Nextstellis can be filed starting from 15th April 2025. Hence, the generic version of this drug is likely to be released after 17 June, 2036.
Nextstellis is primarily used by females of reproductive potential to prevent pregnancy. The effectiveness of Nextstellis stems from its active ingredients, Drospirenone and Estetrol.
Nextstellis holds 2 patents. The last drug patent for Nextstellis is due to expire on 17 June, 2036. Expect Nextstellis generic to be available after this date. Below are the details of the patent: